THC + CBD for Chronic Kidney Disease
(POT-GFR-PK Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.
Who Is on the Research Team?
Michael Walsh, MD, PhD
Principal Investigator
McMaster University
Are You a Good Fit for This Trial?
This trial is for adults over 25 with chronic kidney disease, including those on hemodialysis. Participants must have a body mass index between 20 and 35, no drug dependence (except caffeine or nicotine), no recent cannabis use, and not be taking certain medications that interact with THC/CBD.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of oral THC and CBD, followed by blood, urine, and dialysate sample collection
Follow-up
Participants are monitored for safety and effectiveness after treatment, including adverse events and vital signs
What Are the Treatments Tested in This Trial?
Interventions
- Tetrahydrocannabinol-Cannabidiol Combination
Find a Clinic Near You
Who Is Running the Clinical Trial?
McMaster University
Lead Sponsor
Center for Medicinal Cannabis Research
Collaborator